NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency says in draft guidance ...

Post-hoc analyses of the EFFISAYIL 2 trial revealed improvements in Psoriasis Symptom Scale (PSS), Pain Visual Analog Scale ...

According to experts, children as young as one year of age can develop psoriatic arthritis - a form of arthritis that’s linked to psoriasis, a chronic skin condition. It usually causes joint pain and ...

“From a systemic agent standpoint, we’ve never had an oral agent approved for psoriasis,” Eichenfield, who is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San ...

Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis. “In the adult space, there are ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for commissioning under Commissioning Medicines for Children in ...

and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and ...